| Fund ID | 805-9954132149 |
| Fund type | Private Equity Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 75% |
| Owned by the adviser or related persons | 20% |
| Owned by funds of funds | 80% |
| Owned by non-U.S. persons | 51% |
| Fund | Type | Gross assets |
|---|---|---|
| US Research Equity Extended Master Fund (cayman) L.P. | Hedge | $6.62B |
| Global Research Equity Extended Master Fund (cayman), L.P. | Hedge | $6.51B |
| Iguazu Master Investors (cayman) L.P. | Hedge | $5.88B |
Wellington Biomedical Innovation Master Investors (cayman) I L.P. reports $130.2 million in gross assets, among the top 38% of private funds by size.
The stated minimum investment is $15 million.
Wellington Biomedical Innovation Master Investors (cayman) I L.P. is managed by Wellington Alternative Investments LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.